At a glance
ClinicalIndex Comparison RecordPhase 3Completed· 251 enrolled
Drug / intervention
Ocriplasmin +1 moredrug
Likely dose
Not stated in record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.
Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.
A Phase III Study of A01016 125μg Intravitreal Injection in Subjects With Symptomatic Vitreomacular Adhesion - Comparison Study to Sham Injection
In Brief
A Phase 3 clinical trial evaluating Ocriplasmin and Sham injection for Symptomatic Vitreomacular Adhesion. Completed, enrolled 251 participants across 1 site.
Detailed Summary
The purpose of this study is to evaluate the superiority regarding vitreomacular adhesion (VMA) resolution of a single intravitreal injection of A01016 (Ocriplasmin) compared to sham-injection in subjects with symptomatic VMA.
Study Details
Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsSymptomatic Vitreomacular Adhesion
CountriesJapan
Collaborators--
Timeline
Phase 3CompletedFinished
2014201520162017201820192020202120222023202420252026
First PostedJun 2013
Enrollment StartJul 2013
Primary CompletionSep 2014
TodayJul 2026
First PostedJun 28, 2013
Enrollment StartJul 1, 2013
Primary CompletionSep 1, 2014
TodayJul 2, 2026
Enrollment to primary: 1.2 yearsPosted 13.0 years ago
Interventions
Ocriplasmindrug
Sham injectiondrug